Breaking News

Orion, Bayer Enter Global Development Pact

June 2, 2014

To develop and commercialize ODM-201 to treat prostate cancer

Orion Corp. and Bayer have entered a global partnership for the development and commercialization of ODM-201, an investigational oral androgen receptor inhibitor entering Phase III development for the treatment of prostate cancer.
 
The companies will jointly develop ODM-201, with Bayer covering the majority of development costs and responsibility for global commercialization. Orion has the option to co-promote ODM-201 in Europe and will manufacture the product. Orion will receive €50 million upfront and is eligible to receive development milestones, tech transfer and commercialization milestones, as well as royalties on sales.
 
Dr. Reijo Salonen, senior vice president of R&D at Orion said, "Joining forces with Bayer, I believe that we have again achieved a collaboration that represents the best of all worlds," said Dr. Reijo Salonen, senior vice president R&D and chief medical officer for Orion. "Bayer has recently committed to developing therapies in Oncology, particularly for Prostate Cancer. At Orion, we continue our track record of inventing innovative molecules. And most importantly, for patients with prostate cancer, this partnership will bring a medicine that will make an important difference to their lives."

Dr. Joerg Moeller, member of the Bayer HealthCare Executive Committee and head of Global Development, said, "We see in ODM-201 a potential new treatment for patients with high risk non-metastatic castration-resistant prostate cancer and are looking forward to developing this promising compound," said Dr. Joerg Moeller, Member of the Bayer HealthCare Executive Committee and Head of Global Development. "From a clinical perspective, ODM-201 has the potential to complement our portfolio in prostate cancer and enables us to deliver new treatment options for patients who desperately need them."
 

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems